Form 4: Elanco Executive Receives Stock Options and Restricted Stock Units

Jose Manuel Correia de Simas, an Executive Vice President at Elanco Animal Health, received stock options and restricted stock units, and disposed of common stock according to a recent SEC Form 4 filing.

Summary

• On March 3, 2025, Jose Manuel Correia de Simas, an Executive Vice President at Elanco Animal Health, engaged in transactions involving Elanco's stock.
• Correia de Simas acquired 22,105 shares of common stock and disposed of 81,400 shares.
• He also received options to purchase 46,383 shares of common stock at an exercise price of $11.31, which vest in three equal installments on March 3, 2026, March 3, 2027, and March 3, 2028, and expire on March 3, 2035.
• Additionally, he acquired 1,830 deferred stock units that vest on December 31, 2026, and settle upon termination of employment.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the grant of stock options is generally positive, the disposal of shares introduces a slightly negative element. Overall, it's a routine transaction.

Positives

• The grant of stock options and restricted stock units to an executive could be seen as a positive sign, aligning the executive's interests with those of the shareholders.

Negatives

• The disposal of 81,400 shares by the executive could be interpreted negatively by some investors.

Risks

• Executive stock transactions can sometimes be misinterpreted by the market, leading to short-term price volatility.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules for the stock options and restricted stock units suggest a multi-year commitment from the executive.

Industry Context

Executive compensation packages, including stock options and restricted stock units, are common in the animal health industry to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in publicly traded companies, including those in the animal health sector.
• Companies like Zoetis and Merck Animal Health also utilize stock options and restricted stock units as part of their executive compensation plans.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term value creation.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholders, depending on how the market interprets the executive's actions.
• The grants incentivize the executive, potentially benefiting the company and its stakeholders in the long run.

Key Dates